

1 **Title:** Association of Nirmatrelvir/Ritonavir treatment and COVID-19 neutralizing antibody titers  
2 in a longitudinal healthcare worker cohort

3

4 Slade Decker, BS<sup>2</sup>

5 Shaoming Xiao, MSPH<sup>2</sup>

6 Carly Dillen, PhD<sup>3</sup>

7 Christina M. Schumacher, PhD, MHS<sup>2</sup>

8 Aaron M. Milstone, MD, MHS<sup>1,2</sup>

9 Matthew Frieman, PhD<sup>3</sup>

10 Amanda K. Debes, PhD, MS<sup>1</sup>

11 <sup>1</sup> Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

12 <sup>2</sup> Johns Hopkins University School of Medicine, Baltimore, MD, USA

13 <sup>3</sup> Center for Pathogen Research, Department of Microbiology and Immunology, University of  
14 Maryland School of Medicine, Baltimore MD 21212

15

16 **Correspondence:**

17 Amanda K. Debes PhD, MS

18 Department of International Health

19 615 N. Wolfe Street, E5036

20 Baltimore, MD 21205

21 [adebes1@jhu.edu](mailto:adebes1@jhu.edu)

22

23 **Manuscript Word Count:** 1386

24

25

26

27 **Abstract**

28 Nirmatrelvir/Ritonavir (NMV/r) is used for the treatment of COVID-19 infection. However,  
29 rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing  
30 antibodies to the SARS-CoV-2 spike protein before and after infection in people who did and did  
31 not take NMV/r to determine if NMV/r impedes the humoral immune response.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

## 53 **Introduction**

54 In 2021, the United States Food and Drug Administration granted Emergency Use  
55 Authorization to Nirmatrelvir/Ritonavir (NMV/r) for the treatment of mild-to-moderate COVID-19  
56 infection. Soon after, the United States began providing anti-viral medication at no cost to  
57 patients to reduce COVID-19 related hospitalizations and mortality. Reports then emerged of  
58 rebound COVID-19 infections, defined as detectable viremia and/or symptoms, two to eight  
59 days after completing NMV/r treatment [1-3]. One hypothesis to explain post-treatment rebound  
60 infection is that early viral suppression reduces the immune response, including antibody  
61 production, thereby predisposing to recurrent viremia and symptoms [4-6]. Prior studies have  
62 found that for other viruses, in addition to SARS-CoV-2, early viral suppression can weaken  
63 immune response to infection [4-5]. Our objective was to examine neutralizing antibodies to the  
64 SARS-CoV-2 spike protein before and after infection in people who did and did not complete an  
65 NMV/r treatment course to elucidate whether NMV/r impedes humoral immune response to  
66 SARS-CoV-2.

## 67 **Methods**

### 68 *Study Population*

69 Healthcare workers (HW) were consented into an ongoing seroprevalence cohort beginning in  
70 June 2020. Approximately every two to six months, HW provided serum samples and completed  
71 surveys that captured data including COVID-19 infection dates and NMV/r use. We measured  
72 changes in neutralization antibody levels using pre-/post-infection serum samples from each  
73 individual meeting inclusion criteria and compared changes in neutralization antibody levels by  
74 NMV/r use. HW who received NMV/r (treated) were matched to a HW who did not (untreated).  
75 Inclusion criteria included: 1) COVID-19 infection (positive PCR or antigen test); 2) no prior  
76 infection or receipt of vaccine dose within 90 days of pre-infection serum collection; 3) had  
77 serum collected and stored within 90 days before infection, 4) had serum collected and stored at

78 least 10 days post-infection. Treated HW were matched to untreated HW who had: 1) an  
79 infection date +/- 14 days of a treated HW; and 2) dates of both the pre- and post-infection  
80 serum collection were +/- 7 days of the treated HW serum collection. This study was approved  
81 by the Johns Hopkins University institutional review board.

### 82 *Neutralization assay*

83 Neutralizing antibody titers to the spike protein of SARS-CoV-2 (WA-1) for pre- NMV/r and post-  
84 NMV/r (treated) samples were compared with untreated controls to determine if NMV/r had a  
85 measurable response on neutralizing antibody response to infection. For the neutralization titer  
86 assays (NT), serum samples were heat inactivated at 56°C for 30 min to remove complement  
87 and allowed to equilibrate to room temperature prior to processing for neutralization titer.

88 Samples were diluted in duplicate to an initial dilution of 1:10 followed by 1:2 serial dilutions  
89 resulting in a 12-dilution series with each well containing 100µL. All dilutions were performed in  
90 DMEM (Quality Biological), supplemented with 10% (v/v) fetal bovine serum (heat inactivated,  
91 Sigma), 1% (v/v) penicillin/streptomycin (Gemini Bio-products) and 1% (v/v) L-glutamine (2 mM  
92 final concentration, Gibco). Dilution plates were then transported into the BSL-3 laboratory and  
93 SARS-CoV-2-GFP inoculum was added to each well to result in a multiplicity of infection (MOI)  
94 of 0.01 upon transfer to titering plates. A non-treated, virus-only control and a mock infection  
95 control were included on every plate. The sample/virus mixture was then incubated at 37°C  
96 (5.0% CO<sub>2</sub>) for 1 hour before transferring to 96-well flat bottom plates with confluent Vero-  
97 TMPRSS2 cells. Titer plates were incubated at 37°C (5.0% CO<sub>2</sub>) for 24 hours after cells were  
98 fixed with 10% neutral buffered formalin (Sigma) for at least 1 hour at 4°C as per BSL3 SOP.  
99 Plates were removed from the BSL3 and stained with Hoechst 33342 (Thermo Scientific)  
100 diluted 1:2000 in PBS for 10 minutes. Cells were washed with PBS and imaged with a Celigo  
101 high content imager (Nexcelom).

### 102 *Statistical analyses*

103 The ratio of the half maximal inhibitory concentration (IC50) between matched participants pre-  
104 and post-infection were compared using Wilcoxon signed rank test. Statistical significance was  
105 defined as  $p < 0.05$ . Analyses were performed in R, version 4.2.2 (R Foundation for Statistical  
106 Computing, Vienna, Austria).

## 107 **Results**

108 Of 1353 HW who reported COVID-19 infection, 65 reported NMV/r use, and 32 met  
109 inclusion criteria from which 21 could be matched to a control. We performed neutralization  
110 assays on serum from 21 HW treated and 21 untreated with NMV/r. Of the 42 participants, the  
111 majority were female (86%) and White (90%). Treated participants were older (median: 50.9;  
112 IQR: 44.6-62.0 years) and less frequently female (78% vs. 94%) than untreated participants  
113 (median: 35.5; IQR: 32.6-40.9). Treated and untreated participants did not substantially differ by  
114 pre-existing conditions or prior exposure to SARS-CoV-2 spike protein.

115 The pre-infection and post-infection half maximal inhibitory concentrations (IC50) in the  
116 treated group were lower than in the untreated group (Figure 1A). The median (IQR) NT of the  
117 treated group pre- and post-infection was 980.0 (477.3-2720.3) and 4394.0 (1986.4-7608.4),  
118 respectively (Supplemental Table). The median (IQR) NT of the untreated group pre- and post-  
119 infection was 1247.5 (433.0, 2032.7) and 7316.0 (4335.0, 10834.0) respectively (Supplemental  
120 Table). Of the treated and untreated groups, 67% and 61%, respectively, had an NT greater  
121 than or equal to 800 pre-infection, and 100% of both groups had an NT greater than or equal to  
122 800 post-infection. The ratio of IC50 between the treated and untreated groups pre- and post-  
123 infection were similar (median: 0.64 and 0.76, respectively,  $p = 0.7$ ) (Figure 1B).

## 124 **Discussion**

125 This study demonstrates that taking NMV/r after COVID-19 infection does not impact the  
126 host humoral immune response. Our results show that the range between pre-infection and  
127 post-infection neutralizing antibody titers for the treated and untreated groups was nearly  
128 identical, with median ratios in IC50 values of 0.64 and 0.76, respectively. While this study

129 demonstrates that there is no significant difference in post-infection NT between treated and  
130 untreated groups, it highlights that despite high pre-infection NTs, both groups were still  
131 infected. Other researchers have attempted to create clarity on the NT threshold of protection,  
132 but it remains poorly defined [7].

133 Our goal was to see if NMV/r has an impact on host humoral immune response during  
134 COVID-19 infection and we assessed this by comparing increase of neutralizing antibodies pre-  
135 to post-infection. A recent publication accessing immunoglobulin G (IgG) and Omicron-specific  
136 neutralizing antibodies in individuals taking NMV/r using only post-infection data reported similar  
137 findings, including similar neutralizing antibody levels when taking the medication and when not,  
138 with an overall conclusion that NMV/r treatment does not impact adaptive immune response [8].  
139 Our results suggest that concern about early viral suppression reducing immune response to  
140 infection should not be a barrier or deterrent to taking NMV/r.

141 We believe the observed difference in age may be due to indication bias for treatment  
142 based on age; older age has been associated with higher risk for severe COVID-19 infection,  
143 leading to an increase in older individuals taking NMV/r. The difference in pre-infection and  
144 post-infection NT between the treated and untreated groups may be attributed to the age  
145 differences across study groups. Prior work has found that compared to older people, younger  
146 people produce a higher antibody response to COVID-19 [9-10].

147 Limitations of this study include a small sample size ( $n = 42$ ), and a demographically  
148 homogenous cohort of HW that limits generalizability, although our sample size is significantly  
149 larger than those used in a similar prior study [8]. Secondly, we only performed NT on WA-1  
150 SARS-CoV-2. Despite the antigenic differences between original SARS-CoV-2 and its  
151 numerous variants, including Omicron, we tested only WT WA1 strain as that is an identical  
152 match to the vaccine strain. Our study population consisted entirely of vaccinated individuals, so  
153 using the same strain as the vaccine would result in the most robust responses.

154           The results of this study show that NMV/r medication does not have a significant impact  
155   on humoral immune response post-infection. This finding should reassure those infected with  
156   COVID-19 that they can take NMV/r without negatively impacting their humoral immune  
157   response. More work is needed to break down barriers that have prevented the acceptance of  
158   this drug as an important treatment option for COVID-19. This study examined immune  
159   response relatively soon after infection; future research is needed to examine the impact of  
160   rebound COVID-19 infections on neutralizing antibody titers, and the rate of anti-SARS-CoV-2  
161   antibody degradation in individuals who take NMV/r compared to those who do not over longer  
162   time periods post-infection. Our findings demonstrate that those at high-risk can take NMV/r to  
163   reduce the severity and length of mild to moderate COVID-19 infection without detriment to their  
164   post-infection humoral immune response.

165  
166   **Acknowledgements:** The authors would like to thank Annie Kuh, LuAnn Rezavi, and other  
167   members of the Johns Hopkins Hospital Clinical Immunology Laboratory, Danielle Koontz,  
168   Anushree Aneja and Emily Egbert of the Johns Hopkins Division of Pediatric Infectious  
169   Diseases, and Matt Courtemanche from the Johns Hopkins University School of Medicine. We  
170   would also like to thank Dr. Ralph Baric (UNC Chapel Hill) for providing the SARS-CoV-2-GFP  
171   inoculum. Research reported in this publication was supported in part by the National Institute of  
172   Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award number  
173   K24AI141580 (A.M.), HHSN272201400008C / 0258-0686-4609 (MF and CD), and the  
174   generosity of the collective community of donors to the Johns Hopkins University School of  
175   Medicine and the Johns Hopkins Health System for Covid-19 research.

176  
177   **Conflict of Interest Disclosure:** All authors report no conflicts.


178  
179   **References**

- 180 1. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. Covid-19 rebound after  
181 Paxlovid and molnupiravir during January-June 2022. medRxiv [Preprint]. June 22, 2022  
182 [cited 2023 March 09]. Available from: <https://doi.org/10.1101/2022.06.21.22276724>.
- 183 2. Wang L, Volkow ND, Davis PB, Berger NA, Kaelber DC, Xu R. Covid-19 rebound after  
184 Paxlovid treatment during Omicron Ba.5 vs ba.2.12.1 subvariant predominance period.  
185 medRxiv [Preprint]. August 06, 2022 [cited 2023 Mar 9]. Available from:  
186 <https://doi.org/10.1101/2022.08.04.22278450>.
- 187 3. Boucau J, Uddin R, Marino C, et al. Characterization of Virologic rebound following  
188 Nirmatrelvir-Ritonavir treatment for coronavirus disease 2019 (covid-19). Clin Infect Dis,  
189 **2022**; 76: 526–529.
- 190 4. Charness ME, Gupta K, Stack G, et al. Rebound of SARS-CoV-2 Infection after  
191 Nirmatrelvir–Ritonavir Treatment. N Engl J Med, **2022**; 387:1045-1047.
- 192 5. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus  
193 infection: balancing virus clearance and immunopathology. Semin Immunopathol, **2016**;  
194 38: 71-82.
- 195 6. Rubin R. From positive to negative to positive again-the mystery of why COVID-19  
196 rebounds in some patients who take Paxlovid. JAMA, **2022**; 327: 2380-2382.
- 197 7. Khoury DS, Schlub TE, Cromer D, et al. Correlates of Protection, Thresholds of  
198 Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg  
199 Infect Dis, **2023**; 29: 381-388.
- 200 8. Epling BP, Rocco JM, Boswell KL, et al. Clinical, Virologic, and Immunologic evaluation  
201 of symptomatic coronavirus disease 2019 rebound following Nirmatrelvir/Ritonavir  
202 treatment. Clin Infect Dis, **2023**; 76: 573-581.
- 203 9. Vassilaki N, Gargalionis NG, Bletsas A, et al. Impact of Age and Sex on Antibody  
204 Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek  
205 Healthcare Workers. Microorganisms, **2021**; 9: 1725.



206 10. Shapiro JR, Sitaras I, Park H, et al. Association of Frailty, Age, and Biological Sex with  
207 Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced  
208 Immunity in Older Adults. Clin Infect Dis, **2022**; 75: 61-71.

209  
210 **Figure 1. Antibody response to SARS-CoV-2 by NMV/r use among unmatched and**  
211 **matched pairs.** Panel A: IC50 pre-infection and post-infection among unmatched participants  
212 who took NMV/r (n = 21) and those who did not (n = 21). IC50 values are displayed using a log  
213 scale of 10. Panel B: IC50 ratio of matched participants who took NMV/r versus those who did  
214 not measured between pre-infection and post-infection serum samples (n = 21). The dashed  
215 line represents an equivalent IC50 value (IC50 ratio = 1). IC50 ratio values are displayed using  
216 a log scale of 2.

**A****B**